Table 1.
Patient characteristics and prior therapies.
| Patient | Age (years) | Gender | Ig Isotype | ISS at diagnosis | FISH | Number of prior lines of therapy | PI before/after carfilzomib | Previous ASCT (years prior to diagnosis of TMA) |
|---|---|---|---|---|---|---|---|---|
| 1 | 70 | F | IgGκ | 2 | +1q21; t(4; 14); del17p | 1 | Ixa before/Bor after | N |
| 2 | 69 | F | IgGκ | 2 | N/A | 2 | Bor before | Y (3) |
| 3 | 67 | M | IgGλ | 1 | N/A | 2 | Bor before | Y (11) |
| 4 | 51 | M | IgGκ | 3 | N/A | 1 | Bor before | Y (1) |
| 5 | 66 | M | IgGκ | 3 | +1q21; del13q; del17p | 1 | Ixa before /Bor after | N |
| 6 | 70 | F | IgGλ | 3 | 1q21 | 1 | Bor before | Y (4) |
| 7 | 55 | M | IgGλ | 1 | N/A | 5 | Bor before | Y (12) |
| 8 | 73 | M | IgGλ | 3 | Normal | 1 | Bor before | Y (4) |
| 9 | 73 | F | IgGλ | 3 | +1q21 | 5 | Bor before | N |
| 10 | 47 | M | IgGλ | 2 | t(11;14) | 3 | Bor before | Y (2) |
The table shows age and gender of patients as well as Ig isotype, staging and FISH findings at time of diagnosis. Prior therapies, including previous and subsequent proteasome inhibitor use and stem cell transplant are reported.
F female, M male, del deletion, Bor bortezomib, Ixa ixazomib, PI proteasome inhibitor, ASCT Autologous stem cell transplant, N no history of ASCT, Y patient received ASCT.